The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 78,337 |
| Stock-based compensation | 37,929 |
| Deferred taxes | 14,237 |
| Depreciation and amortization | 91,417 |
| Unrealized gain on investment in equity securities | 2,824 |
| Non-cash operating lease expense | 1,759 |
| Non-cash interest | 1,356 |
| Contingent consideration fair value adjustment | -31,012 |
| Loss (gain) on disposal of assets | -382 |
| Loss on extinguishment of debt | 0 |
| Amortization of inventory step up | 0 |
| Asset impairment charges | 767 |
| Accounts receivable, net | 58,530 |
| Inventories | 5,961 |
| Prepaid expenses and other assets | 5,024 |
| Accounts payable | 15,156 |
| Accrued royalties | 25,871 |
| Income taxes | -15,531 |
| Accrued government rebates | 24,441 |
| Returned goods reserve | 10,229 |
| Accrued expenses, accrued compensation, and other | 2,226 |
| Net cash and cash equivalents provided by operating activities | 185,225 |
| Acquisition of alimera, net of cash acquired-Alimera | 0 |
| Acquisition of product rights, intangible assets, and other related assets | 20,486 |
| Acquisition of property and equipment, net | 13,835 |
| Proceeds from the sale of building | 0 |
| Net cash and cash equivalents used in investing activities | -34,321 |
| Proceeds from convertible notes | 0 |
| Proceeds from term loan | 0 |
| Purchase of capped call transaction | 0 |
| Proceeds from public offering | 0 |
| Payments on contingent consideration | 26 |
| Principal payments on borrowings | 10,156 |
| Debt issuance costs | 0 |
| Repayment on borrowings under credit agreement | 0 |
| Payment of accrued licensor payment | 0 |
| Series a convertible preferred stock dividends paid | 1,157 |
| Proceeds from stock option exercises and espp purchases | 13,604 |
| Treasury stock purchases for restricted stock vests | 12,209 |
| Net cash and cash equivalents (used in) provided by financing activities | -9,944 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -233 |
| Net change in cash, cash equivalents, and restricted cash | 140,727 |
| Cash and cash equivalents, beginning of year | 144,894 |
| Cash, cash equivalents and restricted cash, end of year | 285,621 |
ANIP
ANIP